Skip to main content
OpenTrials
Completed

NCT Number: NCT00494429

Optimizing the Use of Morphine in Pre-Term Neonates

The purpose of this study is to improve the dosing of morphine in critically ill premature neonates.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 week–32 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Children's National Medical Center

Washington D.C., District of Columbia, 20010, United States

About this study

The investigators hypothesize that identifying co-variates predictive of variability in morphine disposition and/or response will provide the scientific basis for rationale and individualized morphine dosing schemes in neonates and young infants.

60 preterm neonates ranging in gestational age from 22 to 32 weeks will be recruited from the NICU. Stratification by gestational age will be done to ensure broad representation. The decision to initiate morphine therapy will be based solely on clinical indications. Prior to morphine dosing, a biochemical assessment of hepatic and renal function will be obtained. A 0.05 mg/kg loading dose of morphine will be given by an intravenous infusion over 30-minutes in preterm neonates with a gestational age of less than 29 weeks, followed by a continuous infusion of 0.005 mg/kg/h, whereas a loading dose of 0.1 mg/kg will be given in preterm neonates with a gestational age of 29 weeks or more followed by a continuous infusion of 0.01 mg/kg/h. Pain assessment will be performed at baseline (prior to study medication administration) and at .5, 1, 2, 4, 8, 12 and 24 hours after the dose. At each of these time points infants will be videotaped for two minutes with two cameras. Videotapes will be scored afterward using standard validated pain assessment tools for preterm infants.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Preterm neonates of both genders and all races
  • postnatal age less than 30 days
  • an indwelling (peripheral or umbilical) arterial line, and
  • a clinical indication for intravenous morphine administration

Exclusion criteria

  • Neonates with severe asphyxia, grade III or IV intraventricular hemorrhage, major congenital malformations/facial malformations, neurological disorders, and those receiving continuous or intermittent neuromuscular blockers.
  • clinical or biochemical evidence of hepatic and renal compromise (including systemic hypoperfusion) or
  • received drugs that are UGT2B7 substrates (including Lorazepam, ibuprofen, valproic acid, naloxone and other morphine derivatives or propanolol)

Treatment and study plan

Morphine

Drug

Gestational Age< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.

Other names: inulin

Primary outcomes

  1. Safety: Infants will have continuous monitoring of vital signs, oxygen saturation, movements and adverse events to determine the safety of morphine.

    Time frame: study duration

  2. Pharmacodynamics: The Neonatal Infant Pain (NIP) and Premature Infant Pain Profile (PIPP) will be performed at baseline, (prior to drug administration)and at pre-determined time intervals after the dose to assess pain for the efficacy of morphine.

    Time frame: study duration

  3. Pharmacokinetics: The concentrations of morphine and its metabolites will be measured in plasma and urine at pre-determined time points and will be used to calculate the formation and elimination clearances of morphine and its metabolites.

    Time frame: study duration

  4. Pharmacogenetics: Impact of genetic variation in the UGT2B7 gene on the formation clearances of the morphine metabolites will be studied as well as the genetic variation in the µ-opioid receptor, COMT, and β-arrestin 2 genes on the PD of morphine use

    Time frame: study duration

Sponsors and collaborators

Lead sponsor

John van den Anker

Other

Collaborators

  • Erasmus Medical Center
  • University of Louisville

Registry information

Official study title

Optimizing Pain Treatment in Pre-Term Neonates

Important dates

Study start
2005
Primary completion
2014
Study completion
2015
First posted
Jun 29, 2007
Registry last updated
Jul 27, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.